Key result
Transcatheter ASD closure matches surgical efficacy but is linked to ~70% fewer complications.
Why the study?
The clinical utility of the Amplatzer septal occluder for secundum ASD closure can only be judged against contemporaneous surgical results.
Does transcatheter closure using the Amplatzer septal occluder improve safety and clinical utility compared to surgical closure in patients with secundum atrial septal defect?
Comparison
Transcatheter closure using Amplatzer septal occluder vs surgical closure
Design
Multicenter nonrandomized concurrent cohort study
Follow-up
6 and 12 months for device group, 12 months for surgical group
Authors
Loading...
May reduce complications versus surgery for secundum ASD; leaves open comparative effectiveness pending RCTs.**[[1]](https://www.structuralheart.abbott/int/fileadmin/content/clinical-research/clinicalinsights-ous/PDFs/59438_Amplatzer_Septal_Occluder_Safety_Clinical_Insight_OUS.
Cohort (n=596)
Yes
Does transcatheter closure using the Amplatzer septal occluder improve safety and clinical utility compared to surgical closure in patients with secundum atrial septal defect?
Absolute Event Rate: 98.5% vs 100%
p-value: p=>0.05
Transcatheter closure of secundum ASD using the Amplatzer septal occluder is a safe and effective alternative to surgical repair, offering similar efficacy with fewer complications and a shorter hospital stay.
Du et al. (2002) conducted a cohort in Secundum atrial septal defect (n=596). Amplatzer septal occluder vs. Surgical closure was evaluated on Primary efficacy success rate (p=>0.05). Transcatheter closure of secundum ASD using the Amplatzer septal occluder had similar primary efficacy success to surgery (98.5% vs 100%, P>0.05) but lower complications (7.2% vs 24.0%, P<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: